secwatch / observer

Earnings Releases

Quarterly and annual results disclosed under 8-K Item 2.02.

8-K items 2.02 JSON
GALT GALECTIN THERAPEUTICS INC

GALECTIN THERAPEUTICS INC reported financial results for the year ended December 31, 2025.

“Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2025.”
BCLI BRAINSTORM CELL THERAPEUTICS INC.

BRAINSTORM CELL THERAPEUTICS INC. reported the full year ended December 31, 2025 results: net income Net loss for the twelve months ended December 31, 2025, was approximately $10.3 million, EPS Net loss per share for the twelve months ended December 31, 2025, and 2024 was $1.11 and $2.31, respectively.

“On March 31, 2026, Brainstorm Cell Therapeutics Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”
PED PEDEVCO CORP

PEDEVCO CORP reported financial results for the quarter and year ended December 31, 2025.

“On March 31, 2026, PEDEVCO Corp. (the "Company") issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
TBRG TruBridge, Inc.

TruBridge, Inc. reported the year ended December 31, 2025 results: revenue $346.8 million, net income GAAP net income of $4.4 million.

“Total revenue of $346.8 million compared to $342.2 million”
TBRG TruBridge, Inc.

TruBridge, Inc. reported the quarter ended December 31, 2025 results: revenue $87.2 million, net income net loss of $5.5 million.

“Total revenue of $87.2 million compared to $88.1 million”
TBRG TruBridge, Inc.

TruBridge, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

“On March 31, 2026, TruBridge, Inc. issued a press release announcing financial information for the fourth quarter and year ended December 31, 2025.”
EUBG ENTREPRENEUR UNIVERSE BRIGHT GROUP

ENTREPRENEUR UNIVERSE BRIGHT GROUP reported the year ended December 31, 2025 results: revenue $5,682,985, net income $1,905,145.

“reported its audited financial results for the year ended December 31, 2025. Full Year 2025 Financial Highlights - Revenue: $5,682,985 for fiscal year 2025, representing a 7.7% increase compared to approximately $5,274,495 for fiscal year 2024. - Net Income: $1,905,145 for fiscal year 2025, representing a 28.1% increase from $1,487,630 for fiscal year 2024.”
SNX TD SYNNEX CORP

TD SYNNEX CORP reported fiscal first quarter ended February 28, 2026 results: revenue $17.2 billion, net income $327 million, EPS $4.04.

“TD SYNNEX Reports Record Fiscal 2026 First Quarter Results • Revenue of $17.2 billion, an increase of 18.1% year over year and significantly above the high end of our outlook. On a constant currency (1) basis, revenue increased by 13.2% year over year. • Non-GAAP gross billings (1) of $25.8 billion, an increase of 24.4% year over year and significantly above the high end of our outlook. On a constant currency (1) basis, non-GAAP gross billings (1) increased by 19.9% year over year. • Diluted earnings per share (“EPS”) of $4.04, and non-GAAP diluted EPS (1) of $4.73, an increase of 68.9% year over year and significantly above the high end of our outlook. • Returned $118 million to stockholders in the form of approximately $80 million of share repurchases and $39 million in dividends. • Announced a quarterly cash dividend of $0.48 per common share, up 9% year over year.”
DOMH Dominari Holdings Inc.

Dominari Holdings Inc. reported preliminary financial results for the year ended December 31, 2025.

“issued a press release announcing its preliminary revenue results for the year ended December 31, 2025”
OMER OMEROS CORP

OMEROS CORP reported fourth quarter and year ended December 31, 2025 results: net income Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, EPS Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million.

“Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results – Conference Call Today at 4:30 p.m. ET”
LNSR LENSAR, Inc.

LENSAR, Inc. reported financial results for the fiscal quarter and year ended December 31, 2025.

“On March 31, 2026, LENSAR, Inc. (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025.”
FEMY FEMASYS INC

FEMASYS INC reported year ended December 31, 2025 results: revenue $2,293,313, net income $18,627,887, EPS ($0.47).

“critical gaps with innovative, safe, and technologically advanced solutions.” Financial Results for Year Ended December 31, 2025 • Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc. • Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025 compared to”
TVRD Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: net income Net loss for the three months ended December 31, 2025, was $7.3 million...For the full year 2025, net loss was $18.2 mil, EPS Basic and diluted net loss per share...for the three months ended December 31, 2025, were a net loss of $(0.78) on a bas.

“On March 31, 2026, Tvardi Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the fiscal quarter and year ended December 31, 2025.”
TOON Kartoon Studios, Inc.

Kartoon Studios, Inc. reported full year ended December 31, 2025 results: revenue $39.4 million.

“For the full year 2025, revenue totaled $39.4 million, up 21% from $32.6 million in 2024”
QIND Quality Industrial Corp.

Quality Industrial Corp. reported fiscal year ended December 31, 2025 results: revenue $16,307,787, net income $(4,603,645).

“we believe the progress has been substantial. This letter provides an overview of what was achieved and what lies ahead. Financial Highlights FY 2025 FY 2024 Change Revenue $ 16,307,787 $ 11,177,567 +45.9 % Gross Profit $ 4,788,780 $ 3,963,263 +20.8 % Gross Margin 29.4 % 35.5 % Operating Expenses $ 5,245,558 $ 3,265,008 +60.7 % Net Loss / (Income) — Reported $”
DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.

“On March 30, 2026, DiaMedica Therapeutics Inc. (the "Company") announced its consolidated financial results for the year ended December 31, 2025.”
COCP Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. reported financial results for the year ended December 31, 2025.

“Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the year ended December 31, 2025”
VYCO VYCOR MEDICAL INC

VYCOR MEDICAL INC reported financial results for the year ended December 31, 2025.

“On March 31, 2026, we issued a press release regarding our financial results for the year ended December 31, 2025.”
WKHS Workhorse Group Inc.

Workhorse Group Inc. reported the quarter and year ended December 31, 2025 results: revenue $9.7 million.

“filed with the Securities and Exchange Commission. --- EX-99.1 (EX-99.1) --- Press Release Workhorse Group Reports Fourth Quarter and Full Year 2025 Results • Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-year • On a pro forma basis, combined company revenue of $34.0 million for full year”
FBIO Fortress Biotech, Inc.

Fortress Biotech, Inc. reported financial results for the year ended December 31, 2025.

“On March 31, 2026, Fortress Biotech, Inc. issued a press release to provide a corporate update and to announce its financial results for the year ended December 31, 2025.”
MRDN Meridian Holdings Inc./NV

Meridian Holdings Inc./NV updated its the fourth quarter and full-year ended December 31, 2025 guidance (initiated).

“On March 31, 2026, Meridian Holdings Inc. (the “Company”, “we” and “us”) issued a press release disclosing its results of operations for the twelve-month period ended December 31, 2025.”
RNGE RANGE IMPACT, INC.

RANGE IMPACT, INC. reported the fiscal year ended December 31, 2025 results: revenue $3.7 million, net income $19.2 million.

“Increased revenues from continuing operations from $0 in 2024 to $3.7 million in 2025 ○ Increased net income from a loss of $9.8 million in 2024 to a gain of $19.2 million in 2025”
AGPU Axe Compute Inc.

Axe Compute Inc. reported the fiscal year ended December 31, 2025 results: revenue $125,284, net income $232.9 million.

“center facilities or GPU hardware; the Company’s platform provides marketplace access to this network on an asset-light model. FULL YEAR 2025 FINANCIAL HIGHLIGHTS Total Revenue: $125,284, derived entirely from the Company’s Drug Discovery Services legacy segment. No compute revenue was recognized in fiscal 2025, as the Axe Compute segment launched in September 2025”
XTNT Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. reported Full Year 2025 results: revenue $134.0 million, net income $5.0 million, EPS $0.03 per diluted share.

“and may be different from non-GAAP finan --- EX-99.1 (EX-99.1) --- Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results Full year 2025 revenue totals $133.9 million, an increase of 14% year-over-year Xtant delivers positive net income, adjusted EBITDA and operating cash flow Total cash of $17.3 million as of December 31, 2025 with an”
XTNT Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. reported Fourth Quarter 2025 results: revenue $32.4 million, net income $0.1 million.

“Fourth quarter 2025 revenue grew 3% to $32.4 million, compared to $31.5 million for the same period in 2024.”
RILY BRC Group Holdings, Inc.

BRC Group Holdings, Inc. reported financial results for the fiscal quarter and year ended December 31, 2025.

“On March 31, 2026 , BRC Group Holdings, Inc. (f/k/a B. Riley Financial, Inc.) (the “Company”) issued a press release reporting its financial results for the fiscal quarter and year ended December 31, 2025.”
KOD Kodiak Sciences Inc.

Kodiak Sciences Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss for the fourth quarter of 2025 was $56.7 million, or $1.04 per share on both a basic and diluted basis.

“On March 31, 2026, Kodiak Sciences Inc. (the “Company”) published a press release reporting the Company’s financial results for the quarter and year ended December 31, 2025 and business highlights.”
BRFH BARFRESH FOOD GROUP INC.

BARFRESH FOOD GROUP INC. reported Full Year 2026 results: revenue $28 to $32 million.

“Updates Full Year 2026 Revenue Guidance to $28 to $32 million and Full Year 2026 Adjusted EBITDA Guidance to $3.2-$3.8 million”
BRFH BARFRESH FOOD GROUP INC.

BARFRESH FOOD GROUP INC. reported First Quarter 2026 results: revenue $5.0 to $5.2 million. Guidance initiated.

“Provides First Quarter 2026 Revenue Guidance of $5.0 to $5.2 million Representing Up to 77% Growth Compared to Prior Year Period”
BRFH BARFRESH FOOD GROUP INC.

BARFRESH FOOD GROUP INC. reported the fiscal year ended December 31, 2025 results: revenue $14.2 million, net income Net loss for the full year of 2025 was $2.7 million.

“Revenue for the full year of 2025 increased 33% to $14.2 million, compared to $10.7 million in the same period of 2024.”
BRFH BARFRESH FOOD GROUP INC.

BARFRESH FOOD GROUP INC. reported the fourth quarter ended December 31, 2025 results: revenue $5.4 million, net income Net loss for the fourth quarter of 2025 improved to $763,000.

“Revenue for the fourth quarter of 2025 increased 94% year-over-year to $5.4 million, compared to $2.8 million in the fourth quarter of 2024.”
PLAY Dave & Buster's Entertainment, Inc.

Dave & Buster's Entertainment, Inc. reported fourth quarter and fiscal year ended February 3, 2026 results: revenue $529.6 million, net income Net loss totaled $39.8 million, or $1.15 per diluted share, EPS $1.15 per diluted share.

“and dining venues, today announced financial results for its fourth quarter and fiscal year ended February 3, 2026. Fourth Quarter 2025 Financial Summary • Revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024. • Comparable store sales decreased 3.3% compared to the same calendar period of fiscal 2024. Excluding the impact from”
RH RH

RH reported financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026.

“On March 31, 2026, RH released its financial results for the fourth quarter and fiscal year 2025, which are available on the investor relations section of its website. Copies of the press release announcing the release of financial results and the financial results are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated herein by reference.”
AUID authID Inc.

authID Inc. reported the Fourth Quarter and Fiscal Year ended December 31, 2025 results: revenue $0.4 million, net income Net loss was $4.0 million, or $0.28 per share, EPS $0.28 per share.

“results for the Fourth Quarter and Fiscal Year ended December 31, 2025. Fourth Quarter 2025 vs. Fourth Quarter 2024 Financial Summary ● Total revenue for the quarter was $0.4 million, compared to $0.2 million a year ago. ● Operating expenses were $4.5 million, compared to $4.9 million a year ago. ● Net loss was $4.0 million, or $0.28 per share, compared to a”
TONX TON Strategy Co

TON Strategy Co reported the full year ended December 31, 2025 results: revenue $12.8 million, net income $(148.6) million.

“Total revenue was $12.8 million, compared to $0.9 million in 2024, and included approximately $4.0 million from staking activities.”
Keenova Therapeutics plc

Keenova Therapeutics plc reported the fourth quarter ended December 31, 2025 results: revenue $543.0 million.

“Today at 8:00 a.m. ET Fourth Quarter 2025 Highlights 3 • Acthar Gel net sales of $205.6 million • XIAFLEX net sales of $156.5 million • Net sales from continuing operations of $543.0 million • Loss from continuing operations expected to be between $105.0 million and $115.0 million. • Adjusted EBITDA from continuing operations expected to be between $210.0 million and”
PVLA PALVELLA THERAPEUTICS, INC.

PALVELLA THERAPEUTICS, INC. reported financial results for full year ending December 31, 2025.

“On March 31, 2026, Palvella Therapeutics, Inc. (the “ Company ”) announced its financial results for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
LBRA 1847 Holdings LLC

1847 Holdings LLC reported the year ended December 31, 2025 results: revenue $48.3 million, net income $66.5 million.

“Consolidated 2025 Financial Highlights: 2025 2024 Change Revenues $48.3 million $15.7 million +207% Gross Profit $23.9 million $7.8 million +208% Operating Income (Loss) $4.0 million $(12.0) million +$16.0 million Net Income (Loss) from Continuing Operations $66.5 million $(106.8) million +$173.3 million Total Adjusted EBITDA $9.8 million $(3.3) million +$13.1 million”
HSDT Solana Co

Solana Co reported financial results for the fiscal quarter and year ended December 31, 2025.

“On March 30, 2026, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing financial results for the fiscal quarter and year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
AQMS Aqua Metals, Inc.

Aqua Metals, Inc. reported financial results for the year ended December 31, 2025.

“Aqua Metals, Inc. issued a press release announcing its results for the year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
SRG Seritage Growth Properties

Seritage Growth Properties reported the year ended December 31, 2025 results: net income ($73.1) million, EPS ($1.30) per share.

“Net loss attributable to common shareholders of ($6.3) million, or ($0.11) per share and ($73.1) million, or ($1.30) per share for the three and twelve months ended December 31, 2025, respectively.”
SRG Seritage Growth Properties

Seritage Growth Properties reported the three months ended December 31, 2025 results: net income ($6.3) million, EPS ($0.11) per share.

“Net loss attributable to common shareholders of ($6.3) million, or ($0.11) per share and ($73.1) million, or ($1.30) per share for the three and twelve months ended December 31, 2025, respectively.”
NNDM Nano Dimension Ltd.

Nano Dimension Ltd. reported the full year ended December 31, 2025 results: revenue $102.4 million, net income $100.4 million. Guidance initiated.

“Full Year 2025 Results: • Revenue: $102.4 million, a 77.3% increase from $57.8 million year-over-year • GM: 33.5%, down from 43.1% year-over-year • Adjusted GM: 46.9%, up from 45.4% year-over-year • Adjusted EBITDA loss: $53.2 million, down from a loss of $63.6 million year-over-year • Net Loss from Continuing Operations: $100.4 million, up from a loss of $99.9 million year-over-year”
NNDM Nano Dimension Ltd.

Nano Dimension Ltd. reported the fourth quarter ended December 31, 2025 results: revenue $35.3 million, net income $33.9 million. Guidance initiated.

“Fourth Quarter 2025 Results: • Revenue: $35.3 million, a 142.4% increase from $14.6 million year-over-year • Gross Margin (“GM”): 37.7%, up from 32.9% year-over-year • Adjusted Gross Margin (“Adjusted GM”): 49.7%, up from 36.3% year-over-year • Adjusted EBITDA loss: $9.8 million, down from a loss of $18.9 million year-over-year • Net Loss from Continuing Operations: $33.9 million, up from a loss of $9.3 million year-over-year • Total cash, cash equivalents, deposits and marketable equity securities: $459.6 million as of December 31, 2025, down from $515.5 million as of September 30, 2025.”
PRPL Purple Innovation, Inc.

Purple Innovation, Inc. reported the full year 2026 results: revenue in the range of $500 to $520 million. Guidance initiated.

“For 2026, the Company currently expects full year revenue to be in the range of $500 to $520 million and adjusted EBITDA in the range of $20 to $30 million.”
PRPL Purple Innovation, Inc.

Purple Innovation, Inc. reported the calendar year ended December 31, 2025 results: revenue $468.7 million, net income $(51.4) million.

“Full year 2025 net revenue was $468.7 million, a decline of 3.9% compared to the full year 2024.”
PRPL Purple Innovation, Inc.

Purple Innovation, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $140.7 million, net income $3.2 million.

“cost structure, supported by what we believe is a clear and disciplined strategy to scale profitably.” Fourth Quarter 2025 Financial Results Fourth quarter 2025 net revenue was $140.7 million, representing growth of approximately 9.1% compared to the fourth quarter of 2024. Growth was driven primarily by the wholesale channel, reflecting a full quarter of expanded”
BYND BEYOND MEAT, INC.

BEYOND MEAT, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2025.

“On March 31, 2026, Beyond Meat, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025.”
KULR KULR Technology Group, Inc.

KULR Technology Group, Inc. reported the year ended December 31, 2025 results: revenue $16,170,404, net income $61,899,782, EPS loss of $1.56 per share.

“Revenue increased 51% to $16,170,404 in 2025 from $10,737,481 in 2024.”
KULR KULR Technology Group, Inc.

KULR Technology Group, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2,863,961, net income $44,261,358, EPS loss of $.97 per share.

“and confidence in our ability to convert technical leadership into long-term shareholder value.” Fourth Quarter 2025 Financial Results: Revenues: Revenue decreased 15% to $2,863,961 in the fourth quarter ended December 31, 2025, from $3,370,594 reported in the same year-ago period. Selling, General and Administrative (SG&A) Expenses: SG&A expenses increased”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.